BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 6-K
BIOLINERX LTD. filed this Form 6-K on 11/08/2018
Document Outline
Entire Document (774 KB)
Subdocument 1 - 6-K - 6-K
Page 1 - WASHINGTON, D.C. 20549
Page 2 - N/A
Page 3 - N/A
Subdocument 2 - EX-99 - PRESS RELEASE
Page 1 - Exhibit 1
Page 2 - Expected significant milestones through end of 2019:
Page 3 - Financial Results for the Third Quarter Ended September 30, 2018
Page 4 - N/A
Page 5 - Conference Call and Webcast Information
Page 6 - Forward Looking Statement
Page 7 - BioLineRx Ltd.
Page 8 - BioLineRx Ltd.
Page 9 - BioLineRx Ltd.
Page 10 - BioLineRx Ltd.
Page 11 - BioLineRx Ltd.
Subdocument 3 - EX-99 - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Page 1 - Exhibit 2
Page 2 - BioLineRx Ltd.
Page 3 - BioLineRx Ltd.
Page 4 - BioLineRx Ltd.
Page 5 - BioLineRx Ltd.
Page 6 - BioLineRx Ltd.
Page 7 - BioLineRx Ltd.
Page 8 - BioLineRx Ltd.
Page 9 - BioLineRx Ltd.
Page 10 - BioLineRx Ltd.
Page 11 - BioLineRx Ltd.
Subdocument 4 - EX-99 - OPERATING AND FINANCIAL REVIEW
Page 1 - Exhibit 3
Page 2 - Overview
Page 3 - AML
Page 4 - Other matters
Page 5 - Principal Partnering and Collaboration Agreements
Page 6 - Recent Company Developments
Page 7 - Capital Resources
Page 8 - Revenues
Page 9 - N/A
Page 10 - N/A
Page 11 - Sales and Marketing Expenses
Page 12 - Results of Operations Overview
Page 13 - Sales and marketing expenses
Page 14 - Comparison of three-month and nine-month periods ending September 30, 2018 and 2017
Page 15 - Off-Balance Sheet Arrangements


Interview with Philip Serlin, CEO
December 2016